


Genetics of Complex Diseases

Governor's Vision Conference: Personalized Medicine

**Salt Lake City, UT
December 5-6, 2006**



Aravinda Chakravarti, PhD
McKusick-Nathans Institute of Genetic Medicine
Johns Hopkins University School of Medicine

Disclosure

Aravinda Chakravarti is a paid member of the Scientific Advisory Board of Affymetrix. This potential conflict of interest is managed by the policies of Johns Hopkins University School of Medicine

Outline of Talk

1. Genetics of complex disease
2. Principles of genetic variation & association mapping
3. International HapMap Project
4. Finding disease genes by whole-genome scanning
5. Genes for QT-interval and Sudden Cardiac Death

Genetics of Complex Disease

THE HUMAN DISEASE BURDEN:

1.5% from single gene disorders (sickle cell anemia, phenylketonuria, etc.)

3.5% from chromosomal anomalies (Down, Turner, Klinefelter syndromes, etc.)

The vast majority have familial aggregation, genetic etiology but complex inheritance

Single gene inheritance of disease is the exception not the rule

THE CURRENT GENETIC PARADIGM:

Newborn screening to identify preventable genetic outcomes

Diagnosis based on phenotype (dysmorphology) and family history

Molecular (DNA-based) and chromosomal diagnosis

Protein replacement therapy

Reproductive choices and genetic counseling

THE DNA REVOLUTION


The Secret of Life

Cracking the DNA code has changed how we live, heal, eat and imagine the future. By Nancy Gibbs

A NY 4-YEAR-OLD WHO LIKES LADYBUGS AND LIGHTNING BOLTS CAN TELL YOU THAT LIFE IS wildly beautiful as far as the eye can see. But it took the geniuses of our time to reveal how beautiful it is. It took the work of the scientists who see it at all—in the molecular workshop of the cell. And Francis Crick did not discover the code, which means they unveiled its power as a code that would reach 6 ft. in length, G and C. Fold it back up, and it shrink to the size of one of our 100 trillion cells,



James Fixx (1932-1984)



**Was Jim Fixx's
Sudden Cardiac Death
preventable?**

Photo-illustration for TIME by Glen Wexler

Genetics is pointing the way to generalized
personalized medicine...
the practice of medicine embracing human genetic
individuality

3 P's: personalized, predictive & preventive medicine
for disease susceptibility and treatment response

Complex inheritance: An Hypothesis

Complex (non-mendelian) inheritance arises from the accumulation of **common polymorphisms** with **small-to-modest** allelic effects at **multiple genes**

Common variants underlying disease can be identified *a priori*

Principles of Genetic Variation

Classification of Genetic Variation by Type

SNPs (single nucleotide polymorphism): 85%

```
AAGTCGATTGACCGAATTAATTAATTGCGGT  
AAGTCGATTGATCGAATTAATTAATTGCGGT
```

INDELs (insertions/deletions), CNVs (copy number variants), micro/macrosatellites: 10%

```
AAGTCGATTGACCGAATTAAATTAATTGCGGT  
AAGTCGATTGACCG -----AATTAAATTGCGGT
```

Inversions, segmental rearrangements: 5%


Characteristics of SNPs

Genetic differences occur about 1 in 1,000 nucleotides for any two genomes compared


In a genome of 3 billion nucleotides that's 3 million variants per individual

Some of these variants are specific to individuals while others are common to many

Overall 10 million SNPs exist...they occur in specific patterns called haplotypes (arrangement of SNPs on a chromosome)



DNA sequence, SNPs and the concept of tagSNPs



Principles of Association mapping

Disease genes that define host-specific differences need to be identified by:

Family-based linkage studies


Population or family-based association studies

Large-scale DNA sequencing

Biomarker (RNA, protein) discovery

Each of these methods are critical

RET mutational spectrum*: rare mutations everywhere




*Largely (but not exclusively) syndromic and severe HSCR

Whenever a mutation has a single origin it can be identified individually or through its association with nearby markers...

...surrogates by virtue of being associated in the population through shared genetic history

linkage disequilibrium (LD) mapping



CFTR cloning assisted by LD Mapping

$\Delta F508$ ~ 70% of all
mutants

$\Delta F508$ modifies
the pancreatic
sufficiency phenotype

Common Gene Variation in Complex Disease

- Case-control studies, comparing the frequencies of common gene variants can identify susceptibility and protective alleles
- Some have multiple identified genes (*)

Phenotype	Gene	Variant
Peptic ulcer	ABO	B
IDDM*	HLA	DR3,4
Alzheimer dementia	APOE	E4
Deep venous thrombosis	F5	Leiden
Falciparum malaria*	HBBE	β^s
AIDS*	CCR5	$\Delta 32$
Colorectal cancer	APC	3920A
NIDDM*	PPAR γ	I2A

Why whole genome association studies?

- 1) We remain woefully ignorant of the fundamental molecular pathophysiology of complex human diseases.
- 2) The genetic paradigm identifies genes in the face of ignorance of the pathways involved.
- 3) Unbiased search across the **whole genome**.
- 4) **Association** studies are (but linkage analysis are not*) efficient for mapping disease genes when the underlying alleles are common (>5%).

(*Success in linkage studies depends on segregation of trait genes in families...segregation frequency decreases when disease alleles are common and many trait genes are homozygotes.)

International HapMap Project

The International HapMap Consortium
A Haplotype Map of the Human Genome.
Nature 437: 1299-1320, 2005.



Haplotype Map of the Human Genome



Goals: provide genotyping information to support efficient and well-powered genetic association studies of human disease

- Define patterns of genetic variation across human genome
- Guide selection of SNPs efficiently to “tag” common variants
- Public release of all data (assays, genotypes): www.HapMap.org

Phase I: 1.3 M markers in 269 people (1 SNP/5kb at 5%+)

Phase II: +2.6 M markers in 270 people(1 SNP/1kb at 5%+)

Finding disease genes:
whole-genome association studies

Why now?

- 1) Human genome reference sequence is complete.
- 2) Improving annotation of function through experiment and evolutionary conservation.
- 3) International HapMap Phase II project nearing completion (>3.5m validated SNPs genotyped in 270 individuals across 4 human populations: www.HapMap.org).



- 4) Availability of large-scale and accurate genotyping and computing technologies.

Designing whole genome association studies: Phenotype

- 1) Susceptibility or protection; disease onset and progression; target organ damage and complications; adverse drug response (pharmacogenetics).
- 2) Qualitative or quantitative measures; reliability and accuracy.
- 3) Demonstrated heritability (twin studies or family studies).

Designing whole genome association studies: Samples

- 1) Family-based (parent-child trios or sibships) or population-based (case-control or case-cohort) studies.
- 2) Sampling the extremes of the population distribution of a quantitative phenotype.
- 3) One stage or multi-stage designs.
- 4) Replication study samples.

Genome-wide Association Studies: Recent Successes in Complex Diseases & Traits

Class variant: variants within a functional class (coding; non-synonymous)

LFA (lymphotoxin α) in myocardial infarction

IFIH1 (interferon induced helicase) in type 2 diabetes

Genome-wide: function-agnostic survey of the entire genome

CFH (complement factor H) in age-related macular degeneration

INSIG2 (insulin-induced gene 2) in BMI/obesity



NOS1AP (nitric oxide synthase adapter protein) in the QT-interval/Sudden Cardiac Death

Genes underlying the QT-interval and Sudden Cardiac Death

QT interval: SCD intermediate trait?


Extremes of QT interval, from rare mutations, lead to sudden death (LQTS, SQTS)

Correlation between QT interval and increased CVD mortality in the general population




NOS1AP (CAPON) affects the QT-interval

ChrI



**CAPON/
NOS1AP**
4.9 ms
($\lambda \sim 1.7$)
36%
1.2%
 $P \sim 10^{-7}$


- Carboxy-terminal PDZ ligand of nNOS
- Expressed in cardiomyocytes
- Competes with PSD95 to interact with nNOS through the PDZ domain



CAPON's role in ICD Firings & SCD

211 cases

$P < 0.026$




Reynolds ICD Registry

Firing = VT/VF

71 cases, 107 controls

$P < 0.025$



Oregon SUDS

(witnessed, un-witnessed & non-resuscitated cardiac arrests)


B = TTGC haplotype associated with increased QT_cRAS

A = all other haplotypes

Whole genome association studies: Opportunities and Challenges

- 1) Understanding genetic architecture of human traits, gene action and disease pathophysiology.
- 2) Improvement of computational methods for gene discovery.
- 3) Detecting gene-gene and gene-environment interactions.
- 4) Replication of results; sharing of results, data and biological samples.
- 5) Finding the causative variants.

DNA Sequencing Revolution



454 LIFE SCIENCES

ABOUT 454* APPLICATIONS NEWS & EVENTS INVESTORS CONTACT

ENABLING TECHNOLOGY SEQUENCING SERVICES PRODUCTS & REAGENTS

The header features a blue background with a large orange DNA double helix on the right and a blue sphere with white dots on the left. The text is in white and orange.



Products

Advancing genetic analysis
one billion bases at a time.™



Home | Contact

More Strands. Bigger Experiments. Better Science.



About Us | Our Team | Our Technology | Investor Relations

Prospects of Personalized Medicine

- 1) Does not need to be universal but should cover the greatest risk variation in the commonest of diseases.
- 2) Increases safety in healthcare?
- 3) Decreases cost of healthcare?
- 4) Need for point-of-care diagnostics and counseling.
- 5) Need sentinel medical examples.
- 6) Is going to be less “racial” than currently assumed.

Prospects of Personalized Medicine

- 1) Does not need to be universal but should cover the greatest risk variation in the commonest of diseases.
- 2) Increases safety in healthcare?
- 3) Decreases cost of healthcare?
- 4) Need for point-of-care diagnostics and counseling.
- 5) Need sentinel medical examples.
- 6) Is going to be less “racial” than currently assumed.

BLOOD TRANSFUSIONS & ABO GENETIC VARIATION